...
首页> 外文期刊>BMJ quality & safety >Challenges of opioid deprescribing and factors to be considered in the development of opioid deprescribing guidelines: a qualitative analysis
【24h】

Challenges of opioid deprescribing and factors to be considered in the development of opioid deprescribing guidelines: a qualitative analysis

机译:阿片类药物剥夺和因素在开发阿片类药物剥夺指导方针方面的挑战:定性分析

获取原文
获取原文并翻译 | 示例
           

摘要

Chronic prescription opioid use is a major international public health issue associated with significant harms, including increased risk of hospitalisation, morbidity and death. Guidance for healthcare professionals on when and how to deprescribe or reduce opioids is required. A key step for guideline development for deprescribing pharmacotherapy is to understand the perspectives of stakeholders. The aim of this study was to explore the perspectives of healthcare professional stakeholders on the challenges associated with opioid deprescribing and factors to be considered in the development of opioid deprescribing guidelines.A qualitative study was undertaken with a purposive sample of healthcare professionals including prescribers, pharmacists and nurses. An initial cohort of participants was identified at the 2018 Australian Deprescribing Network annual meeting and two focus groups were conducted (n=20). Individual interviews were conducted with a further 11 healthcare professionals. Focus groups and interviews were audio-recorded and transcribed verbatim. Data underwent inductive thematic analysis using a phenomenological perspective.Healthcare professionals viewed opioid deprescribing as a challenge and identified several key barriers to deprescribing in clinical practice. Medication, patient, prescriber and health system level challenges were identified. Participants requested evidence-based guidance on the withdrawal of opioid therapies and suggested that prospective opioid deprescribing guidelines require a multitarget, multimodal intervention strategy that addresses patient psychosocial factors and incorporates behavioural change techniques.Opioid deprescribing was perceived as a complex and challenging practice with continued prescribing the default behaviour. Evidence-based opioid deprescribing guidelines may be a valuable resource for clinicians to support clinical decision-making and reduce suboptimal opioid use.
机译:慢性处方阿片类药物使用是一个与重大危害相关的主要国际公共卫生问题,包括增加住院病风险,发病率和死亡。需要在何时以及如何剥夺或减少阿片类药物的何时以及如何剥夺或减少阿片类药物的指导。剥夺药物治疗的指南开发的一个关键步骤是理解利益攸关方的观点。本研究的目的是探讨医疗保健专业利益攸关方对阿片类药物剥夺指导方针所考虑的因素相关的挑战的观点。在包括警察,药剂师等医疗保健专业人士的有目的样本的定性研究和护士。在2018年澳大利亚剥夺网络年度会议上确定了初始参与者队列,并进行了两个焦点小组(n = 20)。个人访谈是通过另外11名医疗保健专业人士进行的。焦点小组和访谈是音频录制和转录的逐字。数据接受了归纳专题分析的使用现象学视角.Healthcare专业人士认为阿片类药物剥夺作为挑战,并确定了临床实践中贬低的几个关键障碍。鉴定了药物,患者,处方者和卫生系统级别挑战。参与者要求关于阿片类药物疗法的撤离的证据指导,并提出了前瞻性阿片类药剥夺指导方针需要多元化的多式化干预策略,以解决患者的心理社会因素,并纳入行为改变技术。剥夺剥夺被认为是一种复杂和挑战性的实践,持续处于持续的处方默认行为。基于循证的阿片类药物剥夺指南可能是临床医生提供临床决策和减少次优阿片类药物使用的宝贵资源。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号